secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-11-09T21:08:26+00:00
Accession:  0001193125-26-453586
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Larimar completes rolling BLA for nomlabofusp in Friedreich's ataxia; cash $128.7M
--------------------------------------------------------------------------------

- Rolling Biologics License Application submitted to FDA seeking accelerated approval of nomlabofusp, a frataxin replacement therapy, for Friedreich's ataxia.
- BLA relies on skin frataxin as a potential novel surrogate endpoint; FDA previously confirmed the data package appears capable of supporting submission and review.
- Preliminary cash, cash equivalents and marketable securities of ~$128.7M as of Sept 30, 2026; quarter-end close still ongoing and figure unaudited.
- Milestones: BLA acceptance early 2027, open-label safety update Q1 2027, U.S. approval mid-2027, launch targeted Q3 2027, if approved.
- FORWARD-FA confirmatory Phase 3 enrolling: double-blind, placebo-controlled, 18 months, ages 2-40, ~two-thirds under 21; Breakthrough and Orphan designations held.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526453586/0001193125-26-453586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526453586/lrmr-20261109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-453586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer